Patent intelligence · US
US 10835517
Methods for treating ocular demodex using isoxazoline parasiticide formulations
Methods for treating ocular demodex using isoxazoline parasiticide formulations
Patent details — US 10835517
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2020
- Expiration
- Nov 12, 2040
- Applicant
- Tarsus Pharmaceuticals, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K31/42, A61K31/422, A61K47/26
Quick answer
US 10835517 (Methods for treating ocular demodex using isoxazoline parasiticide formulations) is held by Tarsus Pharmaceuticals, Inc.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tarsus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/42, A61K31/422, A61K47/26, A61K9/0048, A61K9/08
More from Tarsus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364685
Isoxazoline parasiticide formulations
granted -
US 12257263
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
granted -
US 12213964
Isoxazoline parasiticide formulations
granted -
US 12171750
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 11752137
Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
granted -
US 11690826
Methods for treating demodex blepharitis using lotilaner formulations
granted -
US 11690827
Methods for treating ocular Demodex using lotilaner formulations
granted -
US 11197847
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted
Frequently asked questions
What is US patent 10835517?
US 10835517 (Methods for treating ocular demodex using isoxazoline parasiticide formulations) is held by Tarsus Pharmaceuticals, Inc.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10835517?
Tarsus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 10835517 expire?
Our index shows an expiration date of Nov 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.